A股異動丨凱普生物漲4.71% 中標建設第三方醫學檢驗實驗室項目投資合作方選取項目
格隆匯1月12日丨凱普生物漲4.71%,報35.16元,近五個交易日累計漲幅超20%,最新總市值103億元。凱普生物昨晚公吿稱,公司控股子公司凱普醫學檢驗中標佛山市南海區建設第三方醫學檢驗實驗室項目投資合作方選取項目並收到中標通知書。該機構為“平戰結合”的城市核酸檢測基地,平時檢測能力維持在各1萬管/天,戰時通過迅速調配人員、設備、物資提升至共計不少於20萬管/天,按10合1混採達到不少於200萬人份/天的檢測能力,可基本滿足佛山市南海區1天內完成全員篩查的需求。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.